Editorial · Longform
Perspectives
Op-ed-style writing on contributorship, AI in publishing, evaluation reform, persistent identifiers, and the shape of the research-administration vocabulary.
Perspectives is not yet a separately-tagged section — showing CASRAI’s 60 most recent editorial pieces from the full news index.
House Republicans Tell FDA to Stop Taking Chinese Clinical Trial Data on Faith
Reps. John Moolenaar and Ben Cline asked Acting FDA Commissioner Kyle Diamantas on Aug. 21, 2026 to reject Chinese clinical data absent a recent FDA site audit, after three undisclosed trial deaths surfaced. What sponsors and IRBs relying on China-sourced data should expect next.
Australia’s Research Council Drafts a FAIR Data Policy for Future Grants
The Australian Research Council published a draft FAIR Data Policy on Aug. 11, 2026 for sector feedback, embedding Findable and Accessible requirements into future National Competitive Grants Program schemes. Feedback closes Sept. 16, 2026 — what ARC-funded institutions should check now.
Elsevier’s Non-Renewal of an Editor-in-Chief Triggers a Mass Resignation at Games and Economic Behavior
Elsevier told Games and Economic Behavior’s editor-in-chief his six-year term would end in December; all six editors resigned within weeks, and 58 of 62 advisory editors followed by Aug. 19, 2026. What the collapse of a discipline-leading journal’s editorial board means for authors and institutions.
NIH Stops Counting Policymakers as a ‘Mission-Relevant’ Audience for Funded Research
Internal NIH documents reported by Nature on Aug. 11, 2026 redefine “mission-relevant” stakeholders to exclude policymakers and legislators, putting an estimated 3,700+ FY2025-funded projects with “policy” in the title or abstract at risk and slowing non-competing renewals industry-wide.
NIH Holds a Webinar to Explain Its Unified Funding Strategy, Nine Months In
NIH held a public webinar on 14 August 2026 to explain its Unified Funding Strategy, the framework in effect since January 2026 that lets Institute directors weigh program balance, geographic balance, and workforce needs alongside peer review scores when deciding which meritorious applications get funded.
ORI’s 2025 Annual Report: Only 2 of 177 Closed Cases Were Findings of Misconduct
ORI’s 2025 Annual Report shows that of 177 misconduct cases closed in 2025, only two ended in a formal ORI finding of research misconduct — 82 closed as decline-to-pursue and 43 as no finding, meaning institutional investigations are doing most of the real work in this system.
Department of War Orders Research Security Audits at 30 Universities
The Department of War ordered research security audits at 30 U.S. academic institutions on 17 August 2026, giving them until 31 August to report on foreign collaborations tied to Section 1286 entities and rebranded Confucius Institutes, or risk losing eligibility for future federal research funding.
NSF Replaces 12 Solicitations With Anytime-Submission NOFOs, Backing $1.5B
NSF replaced twelve core disciplinary solicitations with twelve new NOFOs carrying over $1.5 billion, announced 17 August 2026.
The FY 2027 IPPS Rule Makes Joint Replacement Bundles Mandatory Again
The FY 2027 IPPS/LTCH final rule, published 4 August 2026 at 91 FR 49570 and effective 1 October 2026, creates a mandatory nationwide joint replacement bundle (CJR-X) starting 1 January 2028, extends nondiscrimination requirements directly to residency and nursing education programmes under a new 42 CFR 413.84, and reshuffles the quality and Promoting Interoperability measure sets. The operating payment update is 2.3 percent.
FDA Finalises Three Cancer Trial Eligibility Guidances at Once
FDA issued final versions of three cancer clinical trial eligibility guidances on 27 July 2026, announced in the Federal Register on 28 July. Addressed to industry, IRBs and clinical investigators, they say patients with ECOG PS2 should be included unless a rationale for exclusion is stated in the protocol, that laboratory exclusions must not be carried forward automatically from earlier trials, and that measurable clinical parameters should replace time-based washout periods.
Education Department Proposes a Full Rewrite of the Accreditation Rules
The Education Department published a proposed rewrite of the accrediting agency recognition regulations at 34 CFR part 602 on 20 August 2026 (91 FR 53940). It would remove geographic scope limits, eliminate the two-year rule for new agencies, state that recognition confers no antitrust immunity, require viewpoint-neutral decisions, and impose written-reasoning and appeal requirements on transfer of credit denials. The AIM Committee reached consensus on 21 May 2026. Comments close 21 September 2026; earliest effective date 1 July 2027.
CMS Pauses TCET and Proposes Same-Day Coverage for Breakthrough Devices
CMS published the RAPID coverage pathway on 11 August 2026 at 91 FR 51710, under which a proposed national coverage determination would issue the same day as FDA market authorisation and be finalised 60 days later for Class II devices and 90 for Class III. The TCET pathway is paused for new candidates from publication. In vitro diagnostics are excluded. Comments close 13 October 2026 under file code CMS-3487-NC.
CMS Asks Whether CPT Should Stay the National Coding Standard
The CY 2027 Physician Fee Schedule proposed rule, published 16 July 2026 at 91 FR 43842, contains a request for information asking what harms flow from what CMS calls the AMA’s monopoly over CPT-4 licences, what alternatives exist to the CPT and RUC processes, and whether physician procedural services could be paid off ICD-10-PCS instead. A second RFI targets duplicate laboratory and imaging testing. Comments on both close 14 September 2026.
OFCCP Rescinds the EO 11246 Regulations and Ends the Section 503 Disability Goal
Three OFCCP final rules published on 21 August 2026 rescind the Executive Order 11246 regulations, remove the 7 percent Section 503 disability utilization goal and the CC-305 self-identification form, and update coverage thresholds. The Section 503 and VEVRAA rules take effect 21 September 2026; the E.O. 11246 rescission on 26 October. The VEVRAA hiring benchmark and both affirmative action programme requirements survive.
HRSA Relaunches the 340B Rebate Pilot After a Court Vacated the First One
HRSA published a revised 340B Rebate Model Pilot Program on August 3, 2026, eight months after a Maine district court enjoined the first version and six months after it was vacated. Manufacturer plans were due August 24, 2026, approvals are set for September 24, and the effective date is January 1, 2027. Scope is limited to Medicare-negotiated selected drugs, and HRSA has barred manufacturers from denying rebates over diversion or duplicate-discount concerns.
CMS Opens the CLIA Regulations to Public Comment for the First Time Since 1992
CMS and the CDC published a request for information on July 16, 2026 asking what should change in the CLIA regulations at 42 CFR part 493, with comments due September 14, 2026. The questions are specific: AI-assisted postanalytic interpretation, remote competency assessment, factory-calibrated analysers, whether data-only facilities need a CLIA certificate, and blood culture contamination monitoring. It is an RFI, not a proposed rule, and CMS has not committed to any rulemaking.
DOE’s Conflict of Interest and Commitment Rule Is Now in Force
The Department of Energy’s final rule at 2 CFR part 910 subpart C took effect on August 17, 2026, requiring every DOE financial assistance applicant and recipient to hold a written conflict of interest and conflict of commitment policy. Twenty-one commenters, including AAU, COGR and APLU jointly, asked for a one-year lead time; DOE gave thirty days. The 15-day disclosure-update clock is tighter than the PHS standard, and the conflict-of-commitment definition reaches unpaid, honorary and pending appointments.
DOJ Bulk Data Rule and International Research Collaboration
DOJ’s Data Security Program restricts bulk sensitive-data transfers to countries of concern and reaches university data-sharing and vendor agreements.
NSF postdoctoral fellowships in 2026: what’s open, what’s paused
PRFB remains open under NSF 26-504 (deadline September 29, 2026), but MPS-Ascend is archived and SPRF (including its Broadening Participation track) is paused pending a new solicitation as of early 2026 — a status check for applicants and research administrators.
NIH T32 Training Grants: What Changed for FY2026 Stipends and Budgets
NIH’s NOT-OD-26-044 sets FY2026 Kirschstein-NRSA stipend levels for T32 institutional training grants: a flat $29,364 predoctoral rate and tiered postdoctoral rates from $63,480 to $77,076. Tuition/fee allowances are unchanged — here’s what T32 program administrators need to update, and what hasn’t moved.
NIH’s FY2026 Appropriations Are Enacted: What It Means for Grantees Now
Full-year FY2026 appropriations for NIH are enacted at $47.5B via P.L. 119-75, ending the earlier CR period. Here’s what that means for award timing, paylines, and NOA processing now.
DURC-PEPP Oversight in 2026: What Institutions Need in Place While a Federal Revision Is Pending
The 2024 USG DURC-PEPP policy remains the operative framework for institutional biosafety committees even after a May 2025 executive order directed federal agencies to revise or replace it — no superseding text has been issued as of this writing. Here is what IREs, IBCs, and RA offices need in place right now.
JAMA Won’t Retract a 2000 Oxycodone Study, Even After a Co-Author’s Request
JAMA Internal Medicine has declined to retract a 2000 oxycodone-for-osteoarthritis trial despite a co-author briefly backing the request and litigation showing sponsor Purdue Frederick knew of unreported withdrawal symptoms. The journal’s reasoning turns on a narrow standard — fabrication or falsification — that says little about sponsor-level data omission, a gap research-integrity offices should understand.
NIH Loan Repayment Program: What Changes for the FY2027 Cycle
NIH’s extramural Loan Repayment Program consolidates from six subcategories to three for the FY2027 cycle, opening September 1, 2026. What research administration and postdoc offices should track before applicants start.
REF 2029’s SPRE Element: What UK Institutions Need to Know Now
REF 2021’s Environment element becomes SPRE in REF 2029, weighted 20% of the quality profile. What UK research offices should gather evidence for now.
Cureus Delisted From Web of Science: What Changed
Clarivate delisted Cureus from Web of Science in October 2025. What it means for JIF eligibility, researcher CVs, and evaluating mega-journal quality.
Clarivate Lifts Web of Science Hold on Heliyon After 650+ Retractions
Clarivate has restored Web of Science indexing for the Elsevier mega-journal Heliyon, ending a hold placed in September 2024 that followed an internal audit resulting in more than 650 retractions and over 1,000 corrections and expressions of concern.
When a Researcher Should Self-Retract: Lessons From the Porandla Case
A Princeton student’s own request led Wiley to retract her PVC-biodegradation paper in May 2026 — a rare, author-initiated retraction. Here’s the practical decision tree for correction vs. retraction vs. expression of concern, why journals and funders treat self-reporting favorably, and how to document it.
Vanier Canada Graduate Scholarships Discontinued: What Replaced It
Vanier Canada Graduate Scholarships held its final competition in fall 2024 (results April 2025). Canada’s tri-agency funders have folded it into the new Canada Graduate Research Scholarship-Doctoral (CGRS-D) program — here’s what changed and what Canadian research administration offices need to update.
Elsevier Retracts 120+ Papers From Special Issues Over Peer-Review Manipulation
Elsevier has retracted 120+ special-issue articles since June 2026 for systemic peer-review manipulation, with more retractions expected.
ORI Finds Research Misconduct by Former Baylor Nephrology Professor Liping Zhang
A 2025 ORI case summary found that Liping Zhang, PhD, a former Assistant Professor of Nephrology at Baylor College of Medicine, falsified and fabricated western blot and microscopy images across four NIH grant applications (NIDDK, NCI) and three unpublished manuscripts. Zhang did not contest the findings; ORI imposed a two-year debarment and PHS advisory-committee exclusion beginning January 16, 2025.
ORI Finding: Falsified DNA Sequences at Washington State University
ORI found Ryan Evanoff, a former WSU scientific assistant, fabricated and falsified DNA sequencing data in NIH-funded research, resulting in a three-year federal debarment.
What a Student’s Self-Retracted PVC Paper Shows About Authorship and CRediT
A Princeton sophomore’s self-initiated retraction of her sole-authored PVC-biodegradation paper, and her follow-up clarification that she did not personally run the described experiments, is a clean real-world case for research offices: a disclosure gap between calculated/modeled results and reported experimental findings, and how CRediT-style contributor-role statements are built to close exactly that gap.
BMJ Public Health Retracts Mostert COVID-19 Vaccine Paper, Two Years After First Flagging It
BMJ Public Health retracted Saskia Mostert’s COVID-19 vaccine mortality paper on Aug. 11, 2026, roughly two years after first flagging it — after the paper was cited in a June 2026 Senate hearing while still under an unresolved expression of concern.
NSF Is Replacing the PAPPG: The Draft Guidance on Financial Assistance (GFA)
NSF deferred the planned PAPPG 26-1 revision and instead published a draft full replacement, the NSF Guidance on Financial Assistance (GFA), for public comment through Aug. 24, 2026. PAPPG 24-1 plus Policy Notices 26-200 and 26-202 remain current policy today.
Agentic AI Benchmarks Now Measure Real-World Task Completion — Not Just Q&A Accuracy
New agentic leaderboards score AI models on whether they actually finish real tasks, recover from errors, and avoid inventing tools — not on multiple-choice accuracy. For institutions weighing AI agents for literature review, data cleaning, or grant administration, that shift changes what reliable enough to deploy means, and exposes governance gaps in policies built around chatbot use rather than autonomous systems.
The Frontier LLM Landscape in August 2026: Why No Single Model Fits Every Institutional Use
Five frontier models now trade the lead by task and price: Opus 5, Fable 5, GPT-5.6, Grok 4.6, Kimi K3. What that means for institutional AI policy.
Falling AI Token Costs and the New Math of Institutional Budgets
Frontier-model pricing now spans roughly two to three orders of magnitude. What that spread means for how research offices should structure AI-tool budgets and disclosure policy.
Frontier AI Models Now Ship Every Few Days — What That Means for Static AI-Use Policies
Frontier AI labs are now shipping major model updates within weeks of each other. For institutions with static, named-tool AI-use policies, that pace is becoming a real research-integrity problem: disclosure records that name a specific model version can be functionally unauditable by the time anyone needs to rely on them. Here’s what a review cycle built for this pace actually needs to cover.
Claude Fable 5 Tops the AI Writing Leaderboard: What It Means for Disclosure
Claude Fable 5 now leads LMArena’s Text leaderboard for human-preferred writing, narrowly ahead of Opus 4.6/4.7. For research offices, better AI writing quality doesn’t loosen disclosure obligations — it raises the stakes, since more human-like output means detection tools become a weaker backstop.
Gemini 3.7 Flash and the Speed-Cost Case for Institutional AI Tools
Gemini 3.7 Flash is mid-pack on reasoning but the fastest, cheapest model on independent benchmarks. For research-admin screening and triage at scale, that changes the calculus more than the leaderboard rank does.
Claude Opus 5’s Adaptive Reasoning Tiers: What Effort-Level Configuration Means for AI Procurement
Claude Opus 5 turns reasoning effort into a per-query dial (low through xhigh/max) rather than a per-model choice, complicating how institutions license, disclose, and govern AI tools.
Intellia’s One-Time CRISPR Therapy Cuts Angioedema Attacks 87% in Phase 3 Trial
Intellia’s one-time CRISPR therapy lonvo-z met its primary endpoint in the Phase 3 HAELO trial, cutting hereditary angioedema attacks by 87% versus placebo — a still-investigational result now heading into FDA review.
A 2,811-Patient Cohort Just Solved a Mystery Movement Disorder Gene
A gene-burden analysis of 2,811 patients with ataxia, spastic paraplegia, and dystonia identified CD99L2 — previously known only as an immune protein — as a cause of X-linked spastic ataxia, closing a long-standing diagnostic gap.
Denisovans Interbred With Humans at Least Three Separate Times, Yale Study Finds
A Yale-led study reconstructed 832 million base pairs of Denisovan DNA from 177 Near Oceanian genomes, finding evidence of at least three distinct interbreeding events — and thousands of surviving variants still shaping immune response today.
Brain Implant Restores Touch After a Decade
A ten-year clinical trial led by the University of Pittsburgh and University of Chicago found that intracortical microstimulation can safely and durably restore touch sensation in people with spinal cord injury — the longest human study of a brain-computer interface for sensory feedback to date, jointly funded by the NIH BRAIN Initiative and DARPA.
‘Foamy’ Microglia Emerge as a Driver of MS Progression, Study Finds
Lipid-laden ‘foamy’ microglia found in progressive MS lesions may drive disease progression, Dutch researchers report in Nature Neuroscience.
Gut-to-brain: a vagus nerve pathway that shapes memory
A USC rat study in Nature Communications maps a gut-vagus-hippocampus circuit that supports memory after eating, and disrupts under early-life Western diet — work substantially funded by three stacked early-career fellowships (NIA, Quebec FRQS, Alzheimer’s Association) alongside the lab’s NIDDK grants.
Georgetown Study: The Brain Can Rewire Itself for True Multitasking
Georgetown researchers find that with enough practice, learned tasks shift from the prefrontal cortex to the temporal cortex, letting the brain run two tasks in true parallel rather than rapidly switching between them.
Antibody Targeting GPNMB Blocks Spread of Parkinson’s Pathology in Neurons
A Penn Medicine study in Neuron finds that GPNMB, an immune-related protein, helps spread Parkinson’s alpha-synuclein pathology between neurons — and that antibodies blocking GPNMB stopped that spread in lab studies. The paper credits specific NIH awards, including R01 NS115139 and P01 AG084497.
Aging Protein EPS8 Identified as Trigger for ALS and Huntington’s Protein Clumping
A study from the University of Cologne’s CECAD Cluster of Excellence for Aging Research, published in Nature Aging, identifies EPS8 as an aging-linked protein whose rise with age triggers pathological protein aggregation in worm and human cell models of Huntington’s disease and ALS. Reducing EPS8 activity prevented the toxic aggregates and preserved nerve cell function, pointing to a candidate mechanistic link between cellular aging and neurodegenerative disease.
CRISPR Tool Restores Immune Visibility in Prostate Cancer Cells
Duke and Rochester researchers used an RNA-editing CRISPR tool to block a shortening event in the SPSB1 gene’s mRNA, restoring MHC-I antigen display on prostate cancer cells and making tumors visible to the immune system in mouse models.
mRNA Vaccines Get a T Cell Boost From Dendritic Cell ‘Cross-Dressing,’ WashU Study Finds
A WashU Medicine study published in Nature finds that mRNA-LNP vaccines prime CD8+ T cells largely through “cross-dressing” — dendritic cells, including cDC2 cells, picking up ready-made peptide-MHC-I complexes from other cells rather than processing antigen themselves. The mouse-model mechanism depends on type I interferon signaling and helps explain how mRNA vaccines generate robust killer T cell immunity.
Montreal Team Finds a Third Immune Checkpoint T Cells Switch On Themselves
A Université de Montréal/IRCM team reports in Nature that SLAMF6, a receptor T cells trigger on themselves, acts as a third immune checkpoint distinct from PD-1 and CTLA-4 — a preclinical finding with CIHR funding that could open new combination approaches for checkpoint-inhibitor resistance.
FDA Approves Datopotamab Deruxtecan (Datroway) for Triple-Negative Breast Cancer
The FDA has approved datopotamab deruxtecan (Datroway) for unresectable or metastatic triple-negative breast cancer, based on the MSK-led TROPION-Breast02 trial, which showed a roughly six-month overall survival benefit over chemotherapy.
MD Anderson Launches Phase 1 Trial of CD94-Targeted CAR-T Therapy for T/NK-Cell Lymphoma
MD Anderson has opened a Phase 1 trial of JV-394, a CAR-T therapy targeting CD94, in patients with relapsed or refractory T-cell and NK-cell lymphomas, a cancer type that has long resisted cell-based immunotherapy.
FDA Approves ctDNA-Guided Adjuvant Atezolizumab for Bladder Cancer
The FDA has approved atezolizumab (Tecentriq) as adjuvant treatment for muscle-invasive bladder cancer, but only for patients whose blood tests ctDNA-positive after surgery — the first approval to use a blood-based biomarker to gate eligibility for a cancer drug.
Dana-Farber Study Finds a Molecular Brake That Weakens Cancer Vaccines
A Dana-Farber-led study published in Science on July 9, 2026 identifies CARM1, an epigenetic enzyme, as a molecular brake on dendritic cells’ ability to present tumor antigens. Blocking it enhanced how well a cancer neoantigen vaccine primed T cells in preclinical models.
CDK8 Inhibition Pushes Aggressive Pediatric Cancer Cells Toward Normal Muscle
Dana-Farber researchers show CDK8 inhibition slows tumor growth and pushes alveolar rhabdomyosarcoma cells toward normal muscle differentiation.
A Backpack-Sized Field Lab Is Tracking Antimicrobial Resistance in Galápagos Wastewater
A Penn-led team built a backpack-portable microbiology lab to run on-site metagenomic sequencing in the Galápagos, tracking multidrug-resistant bacteria in wastewater-contaminated coastal waters without relying on cold-chain sample shipping.
